Pfizer and Biohaven said a single 75-mg dose of their experimental migraine drug, rimegepant, significantly reduced acute symptoms starting at two hours and lasting for up to 48 hours.

The promising results came from a phase 3 trial with 1,431 participants in China and South Korea that met its primary endpoints of freedom from pain and freedom from most migraine-related symptoms, the companies said.

The drug, which blocks calcitonin gene-related peptide receptors to stop the onset of migraines, was previously FDA-approved for the acute treatment of migraines in February 2020 and as a preventive treatment of episodic migraines in May 2021.

Rimegepant is currently under review by the European Medicines Agency and a marketing authorization decision is expected in the first half of 2022.